Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
This Rapid Response Report from the Canadian Agency for Drugs and Technologies in Health (CADTH) evaluated the efficacy, safety and cost-effectiveness of olopatadine, in comparison with ketotifen, cromolyn, or placebo to assist in the decision making with respect to these agents for the treatment of allergic conjunctivitis.
A limited literature search found that "Treatment of allergic conjunctivitis with olopatadine, ketotifen or cromolyn showed reductions in signs and symptom scores compared to baseline. Both olopatadine and ketotifen were well tolerated. The efficacy results of olopatadine compared to ketotifen were inconsistent. One study of limited quality showed that olopatadine and ketotifen have greater efficacy than cromolyn. There is limited amount of evidence on the cost-effectiveness of olopatadine compared with ketotifen or cromolyn."
The Rapid Response Service is an information service for those involved in planning and providing health care ...
Uncategorized